Plus Therapeutics

Yahoo Finance • 2 days ago

Plus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United Healthcare

We recently published Massive Gains: 10 Stocks Investors Can’t Stop Buying. Plus Therapeutics Inc. (NASDAQ:PSTV) is one of the top performers on Thursday. Shares of Plus Therapeutics soared by 39.29 percent on Thursday to finish at $0.563... Full story

Yahoo Finance • 3 days ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit

CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics, Inc. (NASDAQ: PSTV), has signed a national agreement with UnitedHealthcare insurance company, a unit of UnitedHealth Group Inc. (NYSE: UNH). Effective September 15, the a... Full story

Yahoo Finance • 3 days ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with UnitedHealth... Full story

Yahoo Finance • 6 days ago

Plus Therapeutics receives $1.9M CPRIT payment for cancer program

* Plus Therapeutics (NASDAQ:PSTV [https://seekingalpha.com/symbol/PSTV]) on Monday said that it received a $1.9 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT). * This $1.9 million payment is... Full story

Yahoo Finance • 6 days ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT   

Non-dilutive payment is part of $17.6 million award granted for the Company’s leptomeningeal cancer targeted radiotherapeutic development program HOUSTON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “C... Full story

Yahoo Finance • 10 days ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Certification critical to broad U.S. market release of the CNSide CSF Assay Platform CNSide now meets key federal and state regulatory requirements, including those set by the Centers for Medicare and Medicaid Services (CMS) under the Cli... Full story

Yahoo Finance • 26 days ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

HOUSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central n... Full story

Yahoo Finance • last month

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

HOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous syst... Full story

Yahoo Finance • last month

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting toxicities were observed with an overall... Full story

Yahoo Finance • last month

Plus Therapeutics GAAP EPS of -$0.01 beats by $0.07, revenue of $1.39M misses by $0.44M

* Plus Therapeutics press release [https://seekingalpha.com/pr/20201980-plus-therapeutics-reports-second-quarter-financial-results-and-recent-business-highlights] (NASDAQ:PSTV [https://seekingalpha.com/symbol/PSTV]): Q2 GAAP EPS of -$0.0... Full story

Yahoo Finance • last month

Plus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central n... Full story

Yahoo Finance • last month

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or... Full story

Yahoo Finance • 2 months ago

CNSide diagnostic platform to launch in Texas next month

HOUSTON - Plus Therapeutics, Inc. (NASDAQ:PSTV), a small-cap biotech company with a market capitalization of $27.66 million, announced Thursday that its wholly-owned subsidiary, CNSide Diagnostics, will make its cerebrospinal fluid assay p... Full story

Yahoo Finance • 2 months ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems Company will expand testing services and broaden regional availability over the next 12... Full story

Yahoo Finance • 2 months ago

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

HOUSTON, July 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous syst... Full story

Yahoo Finance • 2 months ago

Leptomeningeal Metastases Market Research Report 2025-2035 | Competitive Analysis of Plus Therapeutics, AstraZeneca, AngioChem, and Y-mAbs Therapeutics

Company Logo Leptomeningeal metastases (LM), the spread of cancer to the brain's and spinal cord's protective tissues, pose severe challenges, stemming from cancers like breast and lung. Rising cancer survival rates have increased LM inci... Full story

Yahoo Finance • 2 months ago

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining Your Approach to Leptomeningeal Metastases” HOUSTON, July... Full story

Yahoo Finance • 3 months ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases Presentations will highlight the clinical utility of the company’s CNS... Full story

Yahoo Finance • 3 months ago

Plus Therapeutics begins treatment in REYOBIQ dose optimization trial

HOUSTON - Plus Therapeutics, Inc. (NASDAQ:PSTV), a micro-cap biotech company with a market capitalization of $15.33 million, has treated its first patients in the ReSPECT-LM dose optimization trial for REYOBIQ (rhenium Re186 obisbemeda) ta... Full story

Yahoo Finance • 3 months ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous syst... Full story